Parenteral Nutrition Market Size, Trends & Forecast 2033

The Parenteral Nutrition Market, estimated at USD 4,839.8 Mn in 2026, is expected to exhibit a CAGR of 6.4% and reach USD 7,471.7 Mn by 2033.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The emerging prevalence of malnutrition among children is expected to bolster the growth of the global parenteral nutrition market. For instance, according to an article published by the World Health Organization, on June 9, 2021, globally, 1.9 billion adults are overweight or obese while 462 million adults are underweight. Moreover, according to the same source, globally, in 2020, it was reported that 149 million children, under the age of five, were estimated to be stunted, 45 million were estimated to be wasted, and 38.9 million were overweight or obese and around 45% of deaths among children, under the age of five years, occur mostly due to under nutrition.

Global Parenteral Nutrition Market - Drivers

Increasing adoption of inorganic strategies such as product approval by regulatory authorities. For instance, in September 2020, Baxter, a global healthcare company, announced that the The U.S. Food and Drug Administration (FDA) approved Clinimix Injections and Clinimix E Injections formulations. It is easier to reach patient protein targets with the new Clinimix formulations as they contain up to 80 g/L of amino acids, the highest amount of protein in any multi-chamber bag currently available in the U.S. also contain less fluid and dextrose than previous formulations.

Global Parenteral Nutrition Market- Restraints

The risk of complications associated with parenteral nutrition is a major factor restraining the growth of the global parenteral nutrition market. Parenteral nutrition, which involves delivering nutrients directly into the bloodstream through an intravenous line, carries inherent risks if not administered properly. Some common complications associated with parenteral nutrition include infections, blood clots, liver problems, and metabolic disturbances. These complications require additional treatment and lengthen hospital stays, increasing the cost of care.

Global Parenteral Nutrition Market- Opportunities

Emerging markets in developing countries present promising growth opportunities for the global parenteral nutrition market. Rapidly developing healthcare infrastructure and rising income levels are expected to drive demand for advanced medical treatments in the emerging region. Countries such as India, China, Brazil and others in Southeast Asia and Latin America are experiencing significant economic development which is improving access to healthcare and expanding the middle-class population. As public health programs are strengthened and more citizens gain health insurance coverage, lifesaving therapies such as parenteral nutrition will become progressively less of a luxury and more of a necessity. This in turn will facilitate wider acceptance and uptake of such medically prescribed nutrition support methods

Global Parenteral Nutrition Market Segmentation

The global parenteral nutrition market report is segmented into nutrition type, application, distribution channel, and region
By nutrition type, vitamins and trace minerals are anticipated to dominate the parenteral nutrition market, accounting for 33.4% of the market in 2026. Growth is supported by their essential role in preventing micronutrient deficiencies among patients receiving intravenous nutrition. In July 2026, Apotex launched generic Infuvite Adult and Pediatric Injections in the U.S., expanding access to parenteral multivitamin therapies across adult and pediatric patient groups.
Based on the patient type, the market is segmented into infants, adults, and geriatric. Out of which, the infants segment is expected to hold a dominant position in the global parenteral nutrition market during the forecast period, and particularly preterm neonates or those with congenital gastrointestinal anomalies, often require parenteral nutrition as their digestive systems may not be fully developed or functional. Infants who are critically ill or those with failure to thrive may also require this support
Based on the application, the market is segmented into diabetes, renal failures, obesity, sarcopenia, cancer, and others (digestive disorders, metabolic syndromes, etc.)). Out of which, the cancer segment is expected to hold a dominant position in the global parenteral nutrition market during the forecast period, and this is attributed increasing prevalence of cancer as Cancer and its treatments can lead to malnutrition due to decreased appetite, alterations in taste, difficulty swallowing, or gastrointestinal complications. PN can provide necessary nutrients when oral or enteral feeding is not possible, helping to prevent or treat malnutrition.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period, and this is attributed to increasing number of hospital pharmacies
Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Out of which, the North America segment is expected to dominate the market over the forecast period, and this is attributed to the increasing demand of parenteral nutrition in that region

Browse 44 Market Data Tables and 40 Figures spread through 180 Pages and in-depth TOC on Global Parenteral Nutrition Market, By Nutrition Type (Carbohydrates, Lipid Emulsion, Lipid Emulsion, Proteins, and Others (Amino acids, etc.)), By Patient Type (Infants, Adults, and Geriatric), By Application (Diabetes, Renal Failures, Obesity, Sarcopenia, Cancer, and Others (Digestive disorders, Metabolic Syndromes, etc.)), By Distribution Channel, (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Key Developments

In June 2026, Fresenius launched its Pedismof range across Europe, expanding its pediatric parenteral nutrition portfolio. Developed by Fresenius Kabi, the ready-to-use three-chamber bags provide age-specific formulations for neonates, infants, children, and adolescents. Each bag combines glucose, amino acids, and SMOFlipid containing fish oil and omega-3 fatty acids. The launch supports standardized nutrition delivery, simplifies clinical preparation, and strengthens Fresenius’ patient-centric innovation strategy across European healthcare settings in participating countries. (Source: Fresenius SE)
In April 2026, Ironwood Pharmaceuticals announced new data for apraglutide, an investigational once-weekly GLP-2 analogue for short bowel syndrome patients dependent on parenteral support. At DDW 2026, healthcare professionals identified fewer weekly TPN days as the most important treatment improvement, supporting innovation in intestinal-rehabilitation therapies that reduce long-term PN dependence. (Source: Ironwood Pharmaceuticals)
In July 2026, Apotex launched four U.S. configurations of generic Infuvite Adult and Pediatric Injections, expanding its hospital injectable portfolio. Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy exclusivity. The products prevent vitamin deficiency in parenteral nutrition patients, covering adults, children aged 11 and older, and pediatric populations. Developed with Orbicular Pharmaceutical Technologies and Gland Pharma, the launch broadens access to affordable parenteral multivitamin therapies across hospitals nationwide. (Source: Apotex)

Link: https://www.coherentmarketinsights.com/market-insight/parenteral-nutrition-market-4804

Key Takeaways of the Global Parenteral Nutrition Market

The global parenteral nutrition market is expected to exhibit a CAGR of 6.4% during the forecast period.
Among regions, North America is expected to be the dominant region with share of 37.1% in the global parenteral nutrition market due to increasing product approval by regulatory authority. For instance, in March 2022, Fresenius Kabi AG, a pharmaceutical company, announced that it had received an approval from the U.S. Food and Drug Administration, SMOFlipid lipid injectable emulsion for pediatric patients requiring parenteral nutrition
Major players operating in the global parenteral nutrition market include AbbVie Inc., Danone, Fresenius Kabi AG, GENTAG, Inc., GSK plc., Nestlé SA, Nutricia, Sun Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, Otsuka Holdings Co., Ltd., and Otsuka Holdings Co., Ltd.